Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 1.00 |
| ▸ | XBP1 | P17861 | 1/20 | 1.00 |
| ▸ | ABCG2 | Q9UNQ0 | 5/20 | 0.80 |
| ▸ | ESR1 | P03372 | 4/20 | 0.76 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.76 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.76 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.76 |
| ▸ | AKR1B10 | O60218 | 2/20 | 0.76 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.76 |
| ▸ | MAOA | P21397 | 1/20 | 0.76 |
| ▸ | PDE5A | O76074 | 1/20 | 0.76 |
| ▸ | IDO1 | P14902 | 1/20 | 0.74 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.70 |
| ▸ | ATM | Q13315 | 1/20 | 0.70 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.70 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.68 |
| ▸ | PRKCA | P17252 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lonchocarpol A SCHEMBL31091681 | 1.00 | MAPT (1.00) | MAPTKMT2AMEN1POLBXBP1 | |
| Lonchocarpol A SCHEMBL144277 | 1.00 | MAPT (1.00) | MAPTKMT2AMEN1POLBXBP1 | |
| SCHEMBL7993201 | 0.91 | MAPT (0.84) | MAPTKMT2AMEN1POLBXBP1 | |
| SCHEMBL8175342 | 0.91 | MAPT (0.84) | MAPTKMT2AMEN1POLBXBP1 | |
| SCHEMBL8002908 | 0.91 | MAPT (0.84) | MAPTKMT2AMEN1POLBXBP1 | |
| SCHEMBL30766285 | 0.91 | MAPT (0.84) | MAPTKMT2AMEN1POLBXBP1 | |
| SCHEMBL24075554 | 0.91 | MAPT (0.83) | MAPTKMT2AMEN1POLBXBP1 | |
| SCHEMBL31570921 | 0.89 | ABCG2 (1.00) | MAPTKMT2AMEN1POLBXBP1 | |
| SCHEMBL16212472 | 0.88 | MAPT (0.78) | MAPTKMT2AMEN1POLBXBP1 | |
| SCHEMBL29851740 | 0.88 | MAPT (0.78) | MAPTKMT2AMEN1POLBXBP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11234918-B2 | Methods for botanical and/or algae extraction | BASF CORPORATION (US) | 2022-02-01 | — | — | US | claimed |
| US-20190046469-A1 | COMPOSITIONS AND METHODS FOR TREATING MOOD DISORDERS OR SKIN DISEASE OR DAMAGE | KUHRTS ERIC HAUSER (US) | 2019-02-14 | — | — | US | claimed |
| EP-2858641-B1 | IMPROVED METHODS FOR BOTANICAL AND/OR ALGAE EXTRACTION | BASF CORP (US) | 2017-09-06 | — | — | EP | claimed |
| US-20150209307-A1 | COMPOSITIONS AND METHODS FOR TREATING MOOD DISORDERS OR SKIN DISEASE OR DAMAGE | KUHRTS ERIC HAUSER (US) | 2015-07-30 | — | — | US | claimed |
| US-20150140141-A1 | METHODS FOR BOTANICAL AND/OR ALGAE EXTRACTION | BASF BEAUTY CARE SOLUTIONS FRANCE SAS (FR) | 2015-05-21 | — | — | US | claimed |
| EP-2858641-A1 | IMPROVED METHODS FOR BOTANICAL AND/OR ALGAE EXTRACTION | BASF Corporation (US) | 2015-04-15 | — | — | EP | claimed |
| WO-2014025989-A1 | COMPOSITIONS AND METHODS FOR TREATING MOOD DISORDERS OR SKIN DISEASE OR DAMAGE | KUHRTS ERIC HAUSER (US) | 2014-02-13 | — | — | WO | claimed |
| US-20140045904-A1 | NIACIN FORMULATIONS AND METHODS WITH REDUCED FLUSHING SIDE EFFECT | KUHRTS ERIC HAUSER (US) | 2014-02-13 | — | — | US | claimed |
| WO-2013184884-A1 | IMPROVED METHODS FOR BOTANICAL AND/OR ALGAE EXTRACTION | BASF CORPORATION (US) | 2013-12-12 | — | — | WO | claimed |
| WO-2012051107-A2 | NIACIN FORMULATIONS AND METHODS WITH REDUCED FLUSHING SIDE-EFFECT | KUHRTS ERIC HAUSER (US) | 2012-04-19 | — | — | WO | claimed |
| US-20120059052-A1 | PRENYLFLAVONOID FORMULATIONS | BIOACTIVES, INC. (US) | 2012-03-08 | — | — | US | claimed |
| US-20110003888-A1 | HOPS EXTRACTION METHODS AND MIXTURES | BIOACTIVES, INC. (US) | 2011-01-06 | — | — | US | claimed |
| US-20090209654-A1 | Prenylflavonoid Formulations | BIOACTIVES, INC. | 2009-08-20 | — | — | US | claimed |
| WO-2008095189-A1 | METHODS AND COMPOSITIONS FOR TREATING DYSLIPIDAEMIA | BIOACTIVES, INC. (US) | 2008-08-07 | — | — | WO | claimed |
| WO-2008089137-A1 | HOPS EXTRACTION METHODS AND MIXTURES | BIOACTIVES, INC. (US) | 2008-07-24 | — | — | WO | claimed |
| EP-1909584-A2 | PRENYLFLAVONOID FORMULATIONS | Bioactives, Inc. (US) | 2008-04-16 | — | — | EP | claimed |
| US-20070218155-A1 | Methods and compositions for treating dyslipidaemia | BIOACTIVES, INC. | 2007-09-20 | — | — | US | claimed |
| WO-2007016578-A2 | PRENYLFLAVONOID FORMULATIONS | BIOACTIVES, INC. (US) | 2007-02-08 | — | — | WO | claimed |
| US-20050032882-A1 | Botanical extract compositions and methods of use | ACTIVEPHYTO TECHNOLOGIES LIMITED (GB) | 2005-02-10 | — | — | US | claimed |
| WO-2004080474-A1 | BOTANICAL EXTRACT COMPOSITIONS WITH ANTI-CANCER OR PHYTOESTROGENIC ACTIVITY COMPRISING PRENYL FLAVONOIDS | THE MEDICAL RESEARCH AND EDUCATION TRUST (US) | 2004-09-23 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11234918-B2 | Methods for botanical and/or algae extraction | ALG1, ALG8, CUTA | MAPT 196/4885KMT2A 4341/4885MEN1 862/4885 |
| US-20120059052-A1 | PRENYLFLAVONOID FORMULATIONS | TP53, CYP46A1, HPGD | MAPT 3025/4885KMT2A 4141/4885MEN1 1161/4885 |
| US-20150209307-A1 | COMPOSITIONS AND METHODS FOR TREATING MOOD DISORDERS OR SKIN DISEASE OR DAMAGE | CUTA, PSEN2, PNN | MAPT 52/4885KMT2A 1595/4885MEN1 1504/4885 |
| US-20190046469-A1 | COMPOSITIONS AND METHODS FOR TREATING MOOD DISORDERS OR SKIN DISEASE OR DAMAGE | CUTA, PSEN2, PNN | MAPT 52/4885KMT2A 1595/4885MEN1 1504/4885 |
| US-20110003888-A1 | HOPS EXTRACTION METHODS AND MIXTURES | HMGB2, HMGB3, HPGDS | MAPT 2474/4885KMT2A 4616/4885MEN1 1381/4885 |
| US-20150140141-A1 | METHODS FOR BOTANICAL AND/OR ALGAE EXTRACTION | ALG1, ALG8, CUTA | MAPT 196/4885KMT2A 4341/4885MEN1 862/4885 |
| US-20050032882-A1 | Botanical extract compositions and methods of use | CYP19A1, ESR1, GPER1 | MAPT 3534/4885KMT2A 2139/4885MEN1 865/4885 |
| US-20140045904-A1 | NIACIN FORMULATIONS AND METHODS WITH REDUCED FLUSHING SIDE EFFECT | NAPRT, NISCH, NAMPT | MAPT 2446/4885KMT2A 3746/4885MEN1 2093/4885 |
| US-20090209654-A1 | Prenylflavonoid Formulations | TP53, CYP46A1, HPGD | MAPT 3025/4885KMT2A 4141/4885MEN1 1161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.